**Author's response to reviews**

**Title:** Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.

**Authors:**

Wataru Matsumiya (ytkmatsu@hotmail.com)  
Shigeru Honda (sighonda@med.kobe-u.ac.jp)  
Sentaro Kusuhara (kusu@med.kobe-u.ac.jp)  
Yasutomo Tsukahara (tsuka@med.kobe-u.ac.jp)  
Akira Negi (negi@med.kobe-u.ac.jp)

**Version:** 3  
**Date:** 10 September 2012  
**Author's response to reviews:** see over
Dear Editors,

We would like to submit a revised manuscript entitled “The effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over 1 year of follow-up.” written by Matsumiya et al. as a research article for “BMC Ophthalmology”.

1) We have stated that intravitreal ranibizumab is a standard treatment for exudative AMD at our hospital, and mentioned about ethical approval and informed consent at the first paragraph in the Methods section.

2) Competing interest section has been added after the Discussion/Conclusion section.

We greatly appreciate if you could consider this paper to be published in “BMC Ophthalmology”.

Sincerely yours,

Shigeru Honda